证券代码：002675 证券简称：东诚药业 公告编号：2025-021 第六届董事会第十次会议决议公告 2025年4月29日，烟台东诚药业集团股份有限公司（以下简称"公司"）在 山东省烟台经济技术开发区长白山路7号公司会议室召开了第六届董事会第十次 会议。会议通知于2025年4月25日以通讯方式送达。会议采用现场结合通讯方式 召开，会议应到董事5人，实到董事5人。公司全体监事和高级管理人员列席了本 次会议。会议由公司董事长由守谊先生主持，会议召开符合《中华人民共和国公 司法》（以下简称"《公司法》"）及《烟台东诚药业集团股份有限公司章程》 （以下简称"《公司章程》"）等有关规定。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司 一、董事会会议召开情况 （一）审议通过了《2025年第一季度报告》 内容详见刊载于《证券时报》、《证券日报》、《中国证券报》、《上海证 券报》和巨潮资讯网（www.cninfo.com.cn）《2025年第一季度报告》。 本议案已经公司董事会审计委员会审议通过。 表决结果：同意 5 票，反对 0 票，弃权 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 686.93 million, representing a year-on-year increase of 6.13% compared to CNY 647.23 million in the same period last year[5]. - Net profit attributable to shareholders decreased by 61.55% to CNY 24.73 million from CNY 64.33 million year-on-year[5]. - Total operating revenue for the current period reached ¥686,928,164.92, an increase of 6.1% compared to ¥647,229,057.46 in the previous period[21]. - Net profit for the current period was ¥17,149,804.60, a decrease of 74.0% from ¥65,930,939.61 in the previous period[22]. - The profit attributable to the parent company's shareholders was ¥24,731,523.19, down from ¥64,327,510.75, representing a decline of 61.6%[22]. - Total comprehensive income for the period was CNY 14,432,666.35, a decrease from CNY 64,043,153.93 in the previous period[23]. - Basic and diluted earnings per share were both CNY 0.0300, down from CNY 0.0780 in the previous period[23]. Cash Flow and Financial Position - The net cash flow from operating activities increased significantly by 168.98%, reaching CNY 114.04 million, compared to a negative cash flow of CNY 165.32 million in the previous year[5]. - Net cash flow from operating activities was CNY 114,036,490.30, a significant improvement from a negative CNY 165,318,835.72 in the previous period[25]. - Cash inflow from investment activities totaled CNY 244,977,797.84, compared to CNY 55,664,969.52 in the previous period[25]. - Net cash flow from financing activities was negative CNY 105,346,407.51, a decline from a positive CNY 577,121,865.51 in the previous period[25]. - The ending balance of cash and cash equivalents was CNY 670,718,795.06, slightly up from CNY 668,932,589.63 in the previous period[25]. - The company’s cash and cash equivalents decreased from 755,972,381.28 CNY to 697,376,537.69 CNY, reflecting a decline of approximately 7.5%[17]. - The company reported a total cash outflow from operating activities of CNY 591,630,360.78, down from CNY 824,778,062.09 in the previous period[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 8.69 billion, a 0.61% increase from CNY 8.63 billion at the end of the previous year[5]. - Total assets increased to ¥8,686,979,590.40 from ¥8,634,677,996.44, showing a growth of 0.6%[19]. - Total liabilities rose to ¥3,287,098,674.03, slightly up from ¥3,263,210,041.55, indicating an increase of 0.7%[19]. - Current liabilities decreased to ¥1,542,348,228.08 from ¥1,753,956,120.72, a reduction of 12.0%[19]. - Non-current liabilities increased to ¥1,744,750,445.95 from ¥1,509,253,920.83, reflecting a rise of 15.6%[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,576, with no preferred shareholders[12]. - The company reported a total of 27,654,757 shares held by PACIFIC RAINBOW INTERNATIONAL, accounting for 3.35% of total shares[14]. - The top ten unrestricted shareholders collectively hold 124,888,049 shares, with Yantai Dongyi Biological Engineering Co., Ltd. being the largest shareholder[14]. Operational Segments - The sales revenue from the raw material drug segment was CNY 321.50 million, up 11.10% year-on-year, primarily due to increased sales of heparin products[9]. - The sales revenue from the formulation segment decreased by 6.78% to CNY 86.63 million, while the nuclear medicine segment saw a slight decline of 0.63% to CNY 231.20 million[13]. Expenses and Financial Management - The company reported a significant increase in financial expenses by 536.48%, attributed to increased interest expenses from equity financing repurchase and reduced exchange gains[13]. - Research and development expenses were ¥44,008,471.83, slightly down from ¥45,209,265.30, a decrease of 2.7%[22]. - The company paid CNY 168,579,902.52 to employees, an increase from CNY 152,583,106.37 in the previous period[25]. - The company experienced a 271.36% increase in credit impairment losses, primarily due to provisions for bad debts on receivables[13]. Future Outlook - The company is currently exploring market expansion opportunities and new product development strategies[15].

烟台东诚药业集团股份有限公司 第六届董事会第三次独立董事专门会议 一、独立董事专门会议召开情况 2025 年 4 月 29 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 召开了第六届董事会第三次独立董事专门会议。会议通知于 2025 年 4 月 25 日以 通讯方式送达，会议应出席独立董事 2 人，实际出席独立董事 2 人，会议的召集、 召开和表决程序符合《公司章程》、《上市公司独立董事管理办法》、《独立董事工 作制度》等规定。 二、会议审议情况 全体独立董事经过审议，审议通过了如下议案： 一、《关于购买控股子公司少数股东股权暨关联交易的议案》 经审核，我们认为：公司本次购买景林景盈所持有的蓝纳成的股份事项，交 易价格根据《增资协议》、《股东协议》及交易各方共同协商确定，不存在损害公 司及公司股东利益的情形。 表决结果：同意 2 票，反对 0 票，弃权 0 票。 独立董事：李方、赵大勇 2025 年 4 月 29 日 ...

Investment Rating - The industry investment rating is "stronger than the market" [3][47]. Core Viewpoints - The approval of Ivosidenib for first-line treatment of NSCLC in China is a significant milestone, being the first to show positive results in a clinical trial comparing it to Pembrolizumab [3]. - The HARMONi-2 trial demonstrated that Ivosidenib significantly improved progression-free survival (mPFS of 11.14 months vs. 5.82 months for Pembrolizumab), with a hazard ratio (HR) of 0.51, indicating a 49% reduction in the risk of disease progression or death [3]. - The interim analysis of overall survival (OS) at 39% maturity showed a 22.3% reduction in mortality risk for Ivosidenib compared to Pembrolizumab (HR=0.777) [3]. Summary by Sections Industry News - Ivosidenib has received approval for a new indication in first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC based on the HARMONi-2 trial results [3]. - The trial involved a randomized comparison of Ivosidenib and Pembrolizumab, with primary endpoints focused on progression-free survival (PFS) [3]. - Additional studies have shown Ivosidenib's efficacy in various NSCLC settings, including in combination with chemotherapy [4]. Investment Strategy - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [6]. - Companies to watch include innovative drug developers and those with strong overseas market potential, such as BeiGene, Dongcheng Pharmaceutical, and others [6]. Key Companies to Watch - **Nocera Healthcare**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year growth in sales [7]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [10]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products, particularly in oncology [11]. - **Aier Eye Hospital**: Benefiting from increasing demand for eye care services and a strong pipeline of new products [20].

以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 超长续航模式。 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 资本寒冬，一家上市Bi o t e c h也没有挂掉。 1 8A生物科技七年之痒，7 0家公司（含摘B）仍然整整齐齐，一家没少，即使市值最小 的北海康成账上现金仅剩1亿元，但管理层认为2025年有足够的营运资金，即使诺辉健 康复牌暂时没有进展，但离生死大限还有5个月。 中国创新药处于少年时代，（在上市公司层面）有着足够的容错率和包容度，如同《百 年孤独》中初创的"马孔多"，这里全是年轻人，没有死亡，自然没有墓地。 然而，站在中国创新药1 0年节点之上，两大蜕变还是发生了。 今 非 昔 比 ， 《 创 新 药 供 给 侧 改 革 》 （ 2021 年 7 月 ） 指 出 的 内 卷 和 泡 沫 ， 如 今 都 不 再 严 重。 一是行业主要矛盾的蜕变，从同质化竞争的内部矛盾，转为中国生物科技快速崛起与美 国维持生物科技创新领域领导地位之间的外部矛盾。 二是创 ...

Group 1: Innovation Drug Sector Performance - The Innovation Drug ETF (560900) increased by 1.03% with a turnover of 7.72% and a transaction volume of 2.9414 million yuan as of April 22, 2025 [1] - The CSI Innovation Drug Industry Index (931152) rose by 0.94%, with notable increases in constituent stocks such as Baili Tianheng (688506) up 6.72%, Zhongsheng Pharmaceutical (002317) up 6.41%, and Dongcheng Pharmaceutical (002675) up 4.60% [1] - The Innovation Drug ETF (560900) saw a significant growth of 1.4674 million yuan in scale this month, ranking it 1st among comparable funds [1] Group 2: Market Opportunities and Trends - The innovation drug sector is experiencing new development opportunities, particularly due to changes in trade relations that may lead to increased tariffs on imported drugs from the U.S., benefiting domestic innovative drug products [1] - There is substantial potential for domestic substitution in the fields of blood products, high-end medical devices, and innovative drugs, as China's innovative drug research and development accelerates [1] - The market has shown a continuous rebound in the innovation drug sector, with companies exporting to non-standard markets performing particularly well [1] Group 3: Morgan Asset Management Products - Morgan Asset Management has a range of ETFs including the Morgan Hang Seng Technology ETF (QDII) (513890) and the Morgan China Core Assets ETF (515770), aimed at capturing investment opportunities in technology and carbon neutrality [2] - The firm integrates its "Global Vision Investment Technology" product line to assist investors in seizing investment opportunities in quality technology companies globally [2] - Active management funds focus on emerging industry trends, artificial intelligence, and sectors like new energy vehicles and humanoid robots [2]

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [1]. Core Insights - The commercialization of nuclear medicine is accelerating, with significant growth in diagnostic nuclear drugs and the potential for domestic nuclear drugs to reach a commercialization inflection point [3][17]. - The report highlights the successful commercialization of Pluvicto and Lutathera, which are expected to generate substantial revenues, with Pluvicto projected to exceed $5 billion in peak sales [3][12]. - The report emphasizes the similarities between Radioligand Therapy (RDC) and Antibody-Drug Conjugates (ADC), suggesting that RDC could replicate the success of ADC in the market [3][22]. Summary by Sections Part 1: Overseas Nuclear Drug Rapid Growth, Domestic Commercialization Period - Overseas nuclear drugs are experiencing rapid commercialization, with Pluvicto achieving $1.392 billion in revenue in 2024, a 42% increase, and Lutathera generating $724 million, a 20% increase [3][12]. - The combined revenue from these two drugs for Novartis reached $2.116 billion, indicating the ongoing value realization of nuclear drugs [3][12]. - The report notes that the domestic nuclear drug market is set to expand significantly, with five new nuclear drugs approved since 2020, including Yttrium-90 microspheres from Yuan Da Pharmaceutical, which is expected to generate nearly HKD 500 million in revenue in 2024, a growth rate exceeding 140% [3][20]. Part 2: RDC Expected to Replicate ADC Success Path - RDC shares structural and mechanistic similarities with ADC, consisting of a targeting ligand, a linker, and a radioactive nuclide [3][22]. - The report outlines that both RDC and ADC have followed similar validation timelines, with ADC gaining market traction after the success of Enhertu, while RDC is now gaining attention following the success of Pluvicto [3][22]. - The market for new nuclear drugs is projected to reach approximately $4-5 billion in 2024, comparable to the ADC market size around 2021 [3][22]. Part 3: Domestic Nuclear Drug Pipeline Overview - The report details the current pipeline of domestic nuclear drugs, with three products in the NDA stage, including Novartis's PSMA diagnostic and therapeutic drugs [3][49]. - The leading targets in domestic research remain PSMA, FAP, and SSTR, with companies like Yuan Da Pharmaceutical and Xiantong Pharmaceutical leading in clinical project numbers [3][53]. - The anticipated approval of Novartis's two PSMA-targeted products in Q2 2025 is expected to further stimulate the domestic nuclear medicine market [3][20].

Group 1 - The core viewpoint of the article highlights the significant presence of large private equity firms in the A-share market, with 21 private equity firms holding shares in 51 A-share companies, totaling a market value of 20.2 billion yuan as of April 14 [2] - In the fourth quarter, 16 new stocks were added by private equity firms, 7 stocks were increased, 17 stocks remained unchanged, and 11 stocks were reduced [2] - The distribution of heavy holdings by private equity firms shows that the basic chemical industry had the highest number of stocks at 10, followed by the electronics industry with 9, and both machinery equipment and pharmaceutical biology industries with 6 each [2] Group 2 - Gao Yi Asset held 11 stocks in the fourth quarter, with a total market value of 10.194 billion yuan, including a new investment in Yangnong Chemical of 3.932 million shares valued at 2.275 billion yuan [2] - Gao Yi Asset increased its holdings in Tong Ren Tang, Zhongju High-tech, Zijin Mining, and Ruifeng New Materials, with respective increases of 8.5 million shares, 7.7 million shares, 7.2151 million shares, and 1 million shares, valued at 954 million yuan, 694 million yuan, 5.169 billion yuan, and 619 million yuan [2] - Gao Yi Asset maintained its holdings in Shengyi Technology and Tiandi Technology, with market values of 1.203 billion yuan and 104 million yuan respectively, while reducing its holdings in Yuntianhua, Angel Yeast, Dongcheng Pharmaceutical, and Health元 by 942,400 shares, 10 million shares, 1 million shares, and 1,854,640 shares respectively [3]